AIMS-2-TRIALS - Autism Research For Europe
  • Home
  • About Us
    • About Us
    • FAQs
    • Team
      • Autism-Europe
      • University of Basel
      • Birkbeck, University of London
      • University of Bristol
      • University of Cambridge
      • Central Institute of Mental Health, Mannheim
      • Clinical Foundation for Biomedical Research, Barcelona
      • University of Coimbra
      • Trinity College Dublin
      • European College of Neuropsychopharmacology
      • University of Edinburgh
      • French Alternative Energies and Atomic Energy Commission
      • French National Institute of Health and Medical Research
      • Ghent University
      • University of Glasgow
      • Goethe University Frankfurt
      • University Medical Centre Göttingen
      • University of Groningen
      • Health Services of Madrid
      • Institut Pasteur
      • Karolinska Institute
      • King’s College London
      • Technical University Munich
      • University of Newcastle
      • University of Oxford
      • Radboudumc, Nijmegen
      • Public Hospitals of Paris
      • Policlínica Gipuzkoa Foundation
      • University of Salamanca
      • Stellenbosch University
      • Stella Maris Foundation
      • University Hospitals of Tours
      • Ulm University
      • UMC Utrecht
      • Uppsala University
      • ARTTIC
      • BioSci Consulting
      • DEMCON
      • Noldus
      • Starlab
      • Janssen
      • Novartis
      • Roche
      • Teva
      • UCB Biopharma
      • Autism Speaks
      • Autistica
      • Simons Foundation
    • Project Management
    • Communication
    • Funding
    • EU-AIMS
    • Vacancies
    • Contact Us
  • Autism Community
    • Autism Community
    • Autism Representatives
    • How You Benefit
    • Language
  • Our Research
    • Our Research
    • Biomarkers
    • Testing Medicines
    • Outcome Measures
    • Beyond Medicines
    • Data Analysis
    • Autism Policies
    • Clinical Trials Network
    • Ethics
    • How to get involved
  • News
    • News
    • Publications
Select Page
New AIMS-2-TRIALS database developed by Institut Pasteur

New AIMS-2-TRIALS database developed by Institut Pasteur

Jan 19, 2021 | AIMS-2-TRIALS News

A world-leading AIMS-2-TRIALS team at the Institut Pasteur (Paris) has developed a secure database to address the needs of the AIMS-2-TRIALS project, ensuring that large, multidisciplinary datasets from participants across Europe are secure, GDPR compliant and easily...
Reduced flexible behaviour in autism is driven by less optimal learning

Reduced flexible behaviour in autism is driven by less optimal learning

Jan 19, 2021 | AIMS-2-TRIALS News

AIMS-2-TRIALS researchers from King’s College London have revealed that reduced flexible behaviour in autistic people is underpinned by different dominant learning mechanisms across development, and less optimal learning. Background Flexible behaviour is critical for...
UPDATE: Favourable feedback from European Medicines Agency

UPDATE: Favourable feedback from European Medicines Agency

Jan 19, 2021 | AIMS-2-TRIALS News

Letters of support now available on the EMA website. The AIMS-2-TRIALS consortium has received feedback (qualification advice) from the European Medicines Agency (EMA) on the further exploration of EEG (electroencephalography) as a potential ‘biomarker’ in autism...
Autistic people focus on social information differently to non-autistic people

Autistic people focus on social information differently to non-autistic people

Dec 8, 2020 | AIMS-2-TRIALS News

Over the last decade, researchers have worked hard to identify reliable ways to measure and track the emergence and progression of autism. One promising area of focus has been exploration of how autistic people focus their attention on social cues. Our research In...
Asymmetrical brain patterns can help identify subgroups of autistic people

Asymmetrical brain patterns can help identify subgroups of autistic people

Dec 2, 2020 | AIMS-2-TRIALS News

Autism is a condition that varies a lot between individuals, which means that any therapy or treatment is unlikely to be useful for all autistic people. However, most research does not take such differences between autistic individuals into account. Researchers need...
« Older Entries

Recent Posts

  • New AIMS-2-TRIALS database developed by Institut Pasteur

    January 19, 2021
  • Reduced flexible behaviour in autism is driven by less optimal learning

    January 19, 2021
  • UPDATE: Favourable feedback from European Medicines Agency

    January 19, 2021
  • Exploring the genetics of how infants look at faces and how this may be linked to autism

    January 11, 2021
  • Autistic people focus on social information differently to non-autistic people

    December 8, 2020
  • Contacts
  • Imprint & Disclaimer
  • Privacy Policy
  • Copyright
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI.

Contact    Imprint & Disclaimer   Privacy Policy    Copyright    Twitter    LinkeIn

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA and AUTISM SPEAKS, Autistica, SFARI.

IMI
EU
SFARI
Autistica
AUTISM SPEAKS
AIMS-2-TRIALS